Issues, indications, and controversies regarding intratympanic steroid perfusion

Current Opinion in Otolaryngology and Head and Neck Surgery

Volumn 16, Issue 5, 2008, Pages 434-440

  Hamid, Mohamed ^a   Trune, Dennis ^b  

^a Cleveland Hearing and Balance Center   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

Dexamethasone perfusion; Intratympanic perfusion; Me nieres disease; sudden sensorineural hearing loss

Indexed keywords

DEXAMETHASONE; GLUCOCORTICOID; METHYLPREDNISOLONE; PLACEBO; STEROID;

CLINICAL TRIAL; DRUG BINDING; DRUG EFFECT; DRUG EFFICACY; DRUG MEGADOSE; DRUG RESEARCH; DRUG TREATMENT FAILURE; HEARING LOSS; HUMAN; MEDICAL LITERATURE; MEDICAL PRACTICE; MENIERE DISEASE; NONHUMAN; PERCEPTION DEAFNESS; PRIORITY JOURNAL; REVIEW; SURVIVAL RATE; TREATMENT OUTCOME; ANIMAL; COHORT ANALYSIS; DISEASE MODEL; DOSE RESPONSE; DRUG ADMINISTRATION; DRUG DELIVERY SYSTEM; EARDRUM; FEMALE; INTRALESIONAL DRUG ADMINISTRATION; MALE; PROGNOSIS; RISK ASSESSMENT; SUDDEN DEAFNESS;

ANIMALS; COHORT STUDIES; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG DELIVERY SYSTEMS; FEMALE; HEARING LOSS, SENSORINEURAL; HEARING LOSS, SUDDEN; HUMANS; INFUSIONS, INTRALESIONAL; MALE; MENIERE DISEASE; PROGNOSIS; RISK ASSESSMENT; STEROIDS; TREATMENT OUTCOME; TYMPANIC MEMBRANE;

EID: 58149327225     PISSN: 10689508     EISSN: None     Source Type: Journal    
DOI: 10.1097/MOO.0b013e32830ce796     Document Type: Review

References (74)

1. Sakata E, Kitago Y, Murata Y, Teramoto K. Treatment of Meniere's disease. Middle ear infusion with lidocaine and steroid solution. Auris Nasus Larynx 1986; 13:79-89.
2. Shea JJ Jr, Ge X. Dexamethasone perfusion of the labyrinth plus intravenous dexamethasone for Meniere's disease. Otolaryngol Clin North Am 1996; 29:353-358.
3. Alles MJ, der Gaag MA, Stokroos RJ. Intratympanic steroid therapy for inner ear diseases, a review of the literature. Eur Arch Otorhinolaryngol 2006; 263:791-797.
4. Conlin AE, Parnes LS. Treatment of sudden sensorineural hearing loss: I. A systematic review. Arch Otolaryngol Head Neck Surg 2007; 133:573-581.
5. Hoffer ME, Balough BJ, Gottshall KR. Delivery of drugs to the inner ear. Curr Opin Otolaryngol Head Neck Surg 2006; 14:329-331.
6. Ahn JH, Yoo MH, Yoon TH, Chung JW. Can intratympanic dexamethasone added to systemic steroids improve hearing outcome in patients with sudden deafness? Laryngoscope 2008; 118:279-282.
7. Banerjee A, Parnes LS. Intratympanic corticosteroids for sudden idiopathic sensorineural hearing loss. Otol Neurotol 2005; 26:878-881.
8. Battaglia A, Burchette R, Cueva R. Combination therapy (intratympanic dexamethasone p high-dose prednisone taper) for the treatment of idiopathic sudden sensorineural hearing loss. Otol Neurotol 2008; 29:453-460.
9. ElHennawi DM, ElDeen MH, Abou-Halawa AS, et al. Efficacy ofintratympanic methylprednisolone acetate in treatment of drill-induced sensorineural hearing loss in guinea pigs. J Laryngol Otol 2005; 119:2-7.
10. Fitzgerald DC, McGuire JF. Intratympanic steroids for idiopathic sudden sensorineural hearing loss. Ann Otol Rhinol Laryngol 2007; 116:253-256.
11. Gouveris H, Selivanova O, Mann W. Intratympanic dexamethasone with hyaluronic acid in the treatment of idiopathic sudden sensorineural hearing loss after failure of intravenous steroid and vasoactive therapy. Eur Arch Otorhinolaryngol 2005; 262:131-134.
12. Haynes DS, O'Malley M, Cohen S, et al. Intratympanic dexamethasone for sudden sensorineural hearing loss after failure of systemic therapy. Laryngoscope 2007; 117:3-15.
13. Plaza G, Herraiz C. Intratympanic steroids for treatment of sudden hearing loss after failure of intravenous therapy. Otolaryngol Head Neck Surg 2007; 137:74-78.
14. Stenner M, Jecker P, Gouveris H, Mann W. Treatment of sensorineural hearing loss in acute viral otitis media with intratympanic dexamethasone and hyaluronic acid in comparison with intravenous therapy. Laryngorhinootologie 2006; 85:32-37.
15. Xenellis J, Papadimitriou N, Nikolopoulos T, et al. Intratympanic steroid treatment in idiopathic sudden sensorineural hearing loss: a control study. Otolaryngol Head Neck Surg 2006; 134:940-945.
16. Boleas-Aguirre MS, Lin FR, Della Santina CC, et al. Longitudinal results with intratympanic dexamethasone in the treatment of Meniere's disease. Otol Neurotol 2008; 29:33-38.
17. Garcia-Purrinos FJ, Ferri E, Rosell A, Calvo J. Combined intratympanic and intravenous dexomethasone to control vertigo in Meniere disease. Acta Otorrinolaringol Esp 2005; 56:74-77.
18. Selivanova OA, Gouveris H, Victor A, et al. Intratympanic dexamethasone and hyaluronic acid in patients with low-frequency and Meniere's-associated sudden sensorineural hearing loss. Otol Neurotol 2005; 26:890-895.
19. Garduno-Anaya MA, Couthino DT, Hinojosa-Gonzalez R, et al. Dexamethasone inner ear perfusion by intratympanic injection in unilateral Meniere's disease: a two-year prospective, placebo-controlled, double-blind, randomized trial. Otolaryngol Head Neck Surg 2005; 133:285-294.
20. Silverstein H, Isaacson JE, Olds MJ, et al. Dexamethasone inner ear perfusion for the treatment of Meniere's disease: a prospective, randomized, double-blind, crossover trial. Am J Otol 1998; 19:196-201.
21. Kerr AG, Toner JG. A new approach to surgery for Meniere's disease: talking about surgery. Clin Otolaryngol Allied Sci 1998; 23:263-264.
22. Hamid MA. Intratympanic dexamethasone perfusion in Méniere's disease: seven-year results [abstract]. In: Triologic Combined Middle/Western Section Meeting Abstracts; San Diego, CA, 2006.
23. Conlin AE, Parnes LS. Treatment of sudden sensorineural hearing loss: II. A meta-analysis. Arch Otolaryngol Head Neck Surg 2007; 133:582-586.
24. Ahn JH, Han MW, Kim JH, et al. Therapeutic effectiveness over time of intratympanicdexamethasone as salvage treatment of sudden deafness. Acta Otolaryngol 2007; 1-4.
25. Van Wijck F, Staecker H, Lefebvre PP. Topical steroid therapy using the Silverstein Microwick in sudden sensorineural hearing loss after failure of conventional treatment. Acta Otolaryngol 2007; 127:1012-1017.
26. Hamid M. Recent advances in medical otology-neurotology. Mediterr J Otol 2008:145-153.
27. Parnes LS, Sun AH, Freeman DJ. Corticosteroid pharmacokinetics in the inner ear fluids: an animal study followed by clinical application. Laryngoscope 1999; 109:1-17.
28. Mynatt R, Hale SA, Gill RM, et al. Demonstration of a longitudinal concentration gradient along scalatympani by sequential sampling of perilymph from the cochlear apex. J Assoc Res Otolaryngol 2006; 7:182-193.
29. Plontke SK, Salt AN. Simulation of application strategies for local drug delivery to the inner ear. ORL J Otorhinolaryngol Relat Spec 2006; 68:386-392.
30. Engmer C, Laurell G, Bagger-Sjoback D, Rask-Andersen H. Immunodefense of the round window. Laryngoscope 2008; 118:1057-1062.
31. Plontke SK, Biegner T, Kammerer B, et al. Dexamethasone concentration gradients along scala tympani after application to the round window membrane. Otol Neurotol 2008; 29:401-406.
32. Hamid M,SismanisA. Clinical approach to patients with auditory and vestibular disorders. In: Hamid M, Sismanis A, editors. Medical otology and neurotology. A clinical guide to auditory and vestibular disorders. New York: Thieme; 2006. pp. 43-63.
33. Trune DR, Kempton JB, Gross ND. Mineralocorticoid receptor mediates glucocorticoid treatment effects in the autoimmune mouse ear. Hear Res 2006; 212:22-32.
34. Pondugula SR, Raveendran NN, Ergonul Z, et al. Glucocorticoid regulation of genes in the amiloride-sensitive sodium transport pathway by semicircular canal duct epithelium of neonatal rat. Physiol Genomics 2006; 24:114-123.
35. Ishiyama G, Lopez IA, Ishiyama A. Aquaporins and Meniere's disease. Curr Opin Otolaryngol Head Neck Surg 2006; 14:332-336.
36. Fukushima M, Kitahara T, Fuse Y, et al. Changes in aquaporin expression in the inner ear of the rat after i.p. injection of steroids. Acta Otolaryngol Suppl 2004:13-18.
37. Plontke SK, Siedow N, Wegener R, et al. Cochlear pharmacokinetics with local inner ear drug delivery using a three-dimensional finite-element computer model. Audiol Neurootol 2007; 12:37-48.
38. Cureoglu S, Schachern PA, Rinaldo A, et al. Round window membrane and labyrinthine pathological changes: an overview. Acta Otolaryngol 2005; 125:9-15.
39. Hargunani CA, Kempton JB, DeGagne JM, Trune DR. Intratympanic injection of dexamethasone: time course of inner ear distribution and conversion to its active form. Otol Neurotol 2006; 27:564-569.
40. Rask-Andersen H, Schrott-Fischer A, Pfaller K, Glueckert R. Perilymph/ modiolar communication routes in the human cochlea. Ear Hear 2006; 27:457-465.
41. Plontke SK, Plontke SK, Mynatt R, et al. Concentration gradient along the scala tympani after local application of gentamicin to the round window membrane. Laryngoscope 2007; 117:1191-1198.
42. Salt AN, Sirjani DB, Hartsock JJ, et al. Marker retention in the cochlea following injections through the round window membrane. Hear Res 2007; 232:78-86.
43. Sun JJ, Liu Y, Kong WJ, et al. In vitro permeability of round window membrane to transforming dexamethasone with delivery vehicles - a dosage estimation. Chin Med J (Engl) 2007; 120:2284-2289.
44. Banerjee A, Parnes LS. The biology of intratympanic drug administration and pharmacodynamics of round window drug absorption. Otolaryngol Clin North Am 2004; 37:1035-1051.
45. Ghaheri BA, Kempton JB, Pillers DA, Trune DR. Cochlear cytokine gene expression in murine chronic otitis media. Otolaryngol Head Neck Surg 2007; 137:332-337.
46. Diao M, Gao W, Sun J. Nitric oxide synthase inhibitor reduces noise-induced cochlear damage in guinea pigs. Acta Otolaryngol 2007; 127:1162-1167.
47. Takumida M,TakedaT, TakedaS, et al. Protective effect of edaravone against endolymphatic hydrops. Acta Otolaryngol 2007; 127:1124-1131.
48. Daldal A, Odabasi O, Serbetcioglu B. The protective effect of intratympanic dexamethasone on cisplatin-induced ototoxicity in guinea pigs. Otolaryngol Head Neck Surg 2007; 137:747-752.
49. Tabuchi K, OikawaK, MurashitaH,et al. Protective effects of glucocorticoids on ischemia-reperfusion injury of outer hair cells. Laryngoscope 2006; 116:627-629.
50. Kim HH, Addison J, Suh E, et al. Otoprotective effects of dexamethasone in the management of pneumococcal meningitis: an animal study. Laryngoscope 2007; 117:1209-1215.
51. Adams JC. Clinical implications of inflammatory cytokines in the cochlea: a technical note. Otol Neurotol 2002; 23:316-322.
52. Jang CH, Cho YB, Choi CH, et al. Effect of topical dexamethasone on sensorineural hearing loss in endotoxin-induced otitis media. In Vivo 2007; 21:1043-1047.
53. Eshraghi AA, Adil E, He J, et al. Local dexamethasone therapy conserves hearing in an animal model of electrode insertion trauma-induced hearing loss. Otol Neurotol 2007; 28:842-849.
54. Bird PA, Begg EJ, Zhang M, et al. Intratympanic versus intravenous delivery of methylprednisolone to cochlear perilymph. Otol Neurotol 2007; 28:1124-1130.
55. Trune DR, Kempton JB, Harrison AR, Wobig JL. Glucocorticoid impact on cochlear function and systemic side effects in autoimmune C3.MRL-Faslpr and normal C3H/HeJ mice. Hear Res 2007; 226:209-217.
56. Nin F, Hibino H, Doi K, et al. The endocochlear potential depends on two K+ diffusion potentials and an electrical barrier in the stria vascularis of the inner ear. Proc Natl Acad Sci USA 2008; 105:1751-1756.
57. Gabashvili IS, Sokolowski BH, Morton CC, Giersch AB. Ion channel gene expression in the inner ear. J Assoc Res Otolaryngol 2007; 8:305-328.
58. Moriyama M, Yoshida K, Ichimiya I, Suzuki M. Nitric oxide production from cultured spiral ligament fibrocytes: effects of corticosteroids. Acta Otolaryngol 2007; 127:676-681.
59. Trune DR, Kempton JB, Larrain BE, Hausmann FA. Glucocorticoid and mineralocorticoid induction of cochlear mineralocorticoid receptor-mediated proteins [abstract]. Assoc Res Otolaryngol; 16-21 February 2008; Phoenix; 2008.
60. Lopez IA, Ishiyama G, Lee M, et al. Immunohistochemical localization of aquaporins in the human inner ear. Cell Tissue Res 2007; 328:453-460.
61. Taguchi D, TakedaT, Kakigi A, et al. Expressions of aquaporin-2, vasopressin type 2 receptor, transient receptor potential channel vanilloid (TRPV)1, and TRPV4 in the human endolymphatic sac. Laryngoscope 2007; 117:695-698.
62. Gu FM, Han HL, Zhang LS. Effects of vasopressin on gene expression in rat inner ear. Hear Res 2006; 222:70-78.
63. KitaharaT, Fukushima M, Uno Y, et al. Up-regulation of cochlear aquaporin-3 mRNA expression after intra-endolymphatic sac application of dexamethasone. Neurol Res 2003; 25:865-870.
64. Fukushima M, Kitahara T, Uno Y, et al. Effects of intratympanic injection of steroids on changes in rat inner ear aquaporin expression. Acta Otolaryngol 2002; 122:600-606.
65. Hamid M. Recent advances in medical otology-neurotology. Mediterr J Otol 2006; 2:145-153.
66. Maeda Y, Fukushima K, Kawasaki A, et al. Cochlear expression of adominantnegative GJB2R75W construct delivered through the round window membrane in mice. Neurosci Res 2007; 58:250-254.
67. Praetorius M, Pfannenstiel S, Klingmann C, et al. Expression patterns of nonviral transfection with GFP in the organ of corti in vitro and in vivo. Gene therapy of the inner ear with nonviral vectors. HNO 2008; 56:524-529.
68. Kopke RD, Jackson RL, Coleman JK, et al. NACfor noise: from the bench top to the clinic. Hear Res 2007; 226:114-125.
69. Barkdull GC, Hondarrague Y, Meyer T, et al. AM-111 reduces hearing loss in a guinea pig model of acute labyrinthitis. Laryngoscope 2007; 11 7:2174-2182.
70. Wang J, Pignol B, Chabrier PE, et al. A novel dual inhibitor of calpains and lipid peroxidation (BN82270) rescues the cochlea from sound trauma. Neuropharmacology 2007; 52:1426-1437.
71. Van WijkF, Staecker H, Keithley E, Lefebvre PP. Local perfusion of the tumor necrosis factor alpha blocker infliximab to the inner ear improves autoimmune neurosensory hearing loss. Audiol Neurootol 2006; 11:357-365.
72. Guyot JP, Maire R, Delaspre O. Intratympanic application of an antiviral agent for the treatment of Meniere's disease. ORL J Otorhinolaryngol Relat Spec 2008; 70:21-26.
73. Nakashima T, Naganawa S, Sugiura M, et al. Visualization of endolymphatic hydrops in patients with Meniere's disease. Laryngoscope 2007; 117:415-420.
74. Hamid MA. Dexamethasone ITP vs natural history of Meniere's disease [abstract]. In: ANS COSM Meeting Abstracts; San Diego, CA 2007.